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Abstract
Introduction: Staphylococcus aureus is a common cause of bacterial arthritis, which is associated with progressive
bone loss in affected joints. We recently showed that S. aureus infection also induces a significant systemic bone
loss in mice. This study was performed to assess the effect of estradiol treatment on the clinical course and
outcome of S. aureus arthritis and on infection-induced bone loss in experimental S. aureus infection.
Methods: Mice were ovariectomized, treated with estradiol or placebo, and S. aureus infection was established by
intravenous inoculation of bacteria.
Results: Estradiol treatment was found to decrease significantly the frequency and clinical severity of S. aureus
arthritis, a finding that was accompanied with significantly higher serum levels of interleukin-10 in estradiol-treated
mice. Estradiol was also highly protective against S. aureus-induced systemic trabecular, and cortical bone loss. Lack
of endogenous estrogens and S. aureus infection had additive effects on trabecular bone loss. The S. aureus-
infected, ovariectomized mice lost as much as 76% of their trabecular bone mass.
Conclusions: Treatment with estradiol ameliorates S. aureus arthritis and is protective against infection-induced
systemic bone loss in experimental S. aureus infection.
Introduction
Bacterial arthritis is a disease with high mortality and
morbidity characterized by severe, progressive joint
destruction that occurs despite antibiotic treatment. Sta-
phylococcus aureus is one of the most common causa-
tive pathogens in bacterial arthritis [1], and patients
with underlying joint diseases (for example, rheumatoid
arthritis, or taking immunosuppressive therapy) are at
higher risk for this infection [2]. In a mouse model of
hematogenously spread S. aureus infection, we showed
that the infection, in addition to joint destruction, also
induces pronounced systemic bone loss within a few
days after bacterial inoculation [3]. Even though it is
well known that septic arthritis causes a dramatic bone
loss locally in the affected joints in humans, it remains
to be investigated whether systemic bone loss is seen in
patients with severe bacterial infections, including septic
arthritis. The S. aureus-induced bone loss is likely to be
mediated by osteoclasts, the only known cell type with
bone-resorptive capacity, which can be activated by dif-
ferent proinflammatory cytokines (for example, tumor
necrosis factor (TNF)-a and interleukin (IL)-6) [4,5].
Both these proinflammatory cytokines are increased at
the systemic level of S. aureus-infected mice [6,7], and
TNF-a shows an increased gene expression in the syno-
vium of infected joints [8]. Furthermore, we showed
that TNF-a [9] and interferon (IFN)-g [6] strongly con-
tribute to S. aureus-induced joint destruction. The anti-
inflammatory cytokine IL-10 plays an important role for
control of excessive immunity and damage to the host
during infections [10], and we showed that IL-10 is pro-
tective against S. aureus arthritis, at least partly by inhi-
bition of TNF-a [11]. In addition, IL-10 has been
demonstrated to inhibit osteoclast differentiation in vitro
[12] and to suppress infection-induced bone resorption
in a murine model of periodontitis [13].
Our previous studies showed that osteoclast-inhibiting
treatment with bisphosphonates or receptor activator of
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nuclear factor-B ligand (RANKL)-targeted therapy
reduce the systemic bone loss in S. aureus arthritis in
mice [14,15]. In contrast, the joint destruction was not
affected by these osteoclast-inhibiting therapies.
The female sex hormone estradiol is bone protective
and is likely to prevent osteoporosis both by direct
effects on bone-resorbing osteoclasts and bone-forming
osteoblasts and by immunomodulatory effects changing
the cytokine milieu in the bone compartment. Estradiol
treatment can ameliorate autoimmune arthritis and joint
destruction both in humans and in mice [16-18], and
we previously showed that treatment with estradiol
decreases both the systemic and local bone loss in auto-
immune arthritis in mice [19,20].
The aim of this study was therefore to evaluate the
effect of estradiol on the course and outcome of S. aur-
eus infection, as well as on local and systemic bone loss
in infected mice. Our results clearly show that treatment
with estradiol ameliorates S. aureus arthritis and pro-
tects against S. aureus-induced systemic bone loss.
Materials and methods
Mice
Female C57 BL/6 mice were maintained in the animal
facility at the Department of Rheumatology and Inflam-
mation Research at Göteborg University under standard
light and temperature conditions. Mice were fed labora-
tory chow and tap water ad libitum. Permission from
the local animal research ethics committee, in accor-
dance with national animal welfare legislation, was
obtained for all the mice experiments.
Ovariectomy and estrogen treatment
Ovariectomy or sham operations were performed at 10
weeks of age under isoflurane anesthesia, and carpro-
fen (OrionPharma AB, Sollentuna, Sweden) was used
as postoperative analgesia. Estradiol treatment was
started at ovariectomy. Slow-release pellets (Innovative
Research of America, Sarasota, FL, USA) containing
0.05 mg 17b-estradiol per pellet were implanted subcu-
taneously, giving a release of 0.8 μg 17b-estradiol per
24 hours. As a treatment, control mice were given pla-
cebo-containing subcutaneous pellets (Innovative
Research of America).
Mouse model of systemic S. aureus infection and arthritis
The TSST-1 producing S. aureus strain LS-1, originally
isolated from a spontaneously arthritic NZB/W mouse
[21], was used for induction of septic arthritis. Bacteria
were grown overnight, harvested, and resuspended in
phosphate-buffered saline (PBS) containing 5% bovine
serum albumin and 10% dimethylsulfoxide and kept in
aliquots at -20°C until use. The number of colony-form-
ing units (CFUs) of the bacterial suspension was
determined by performing repeated viable counts. Before
use, bacteria were thawed, washed in PBS, and diluted
to appropriate concentration by calculation with the
previously determined CFUs. Viable counts were per-
formed to determine the actual number of viable bac-
teria given in each experiment. One week after
ovariectomy, mice were inoculated intravenously with 7
to 8 × 107 CFU/mouse of S. aureus LS-1 in 200 μl of
PBS in one of the tail veins.
All mice were followed up individually and checked
daily. Mice were graded blindly for arthritis severity and
frequency. Finger/toe and ankle/wrist joints were
inspected, and arthritis was defined as visible erythema
and/or swelling. To evaluate the intensity of arthritis, a
clinical scoring (arthritic index) was carried out by using
a system in which macroscopic inspection yielded a
score of 0 to 3 points for each limb (0, neither swelling
nor erythema; 1, mild swelling and/or erythema; 2, mod-
erate swelling and erythema; and 3, marked swelling and
erythema). The total score was calculated by adding all
the scores for each animal tested.
The overall condition of each mouse was examined
daily by assessing signs of systemic inflammation (that
is, weight decrease, reduced alertness, and ruffled coat).
In cases of severe systemic infection, when a mouse was
judged too ill to survive another 24 hours, it was culled
and defined as dead due to sepsis.
Mice were killed, and blood, kidneys, and limbs were
obtained on days 3, 7, and 14 after bacterial inoculation.
Histology of inflamed joints
Histopathologic examination of the joints was per-
formed after routine fixation, decalcification, and paraf-
fin embedding. Tissue sections from fore- and hindpaws
were cut and stained with hematoxylin-eosin. All the
slides were coded and evaluated by two blinded obser-
vers. The specimens were evaluated with regard to syno-
vial hypertrophy/infiltration of leukocytes and cartilage/
subchondral bone erosion. The degree of synovitis and
erosion yielded a score from 0 to 3 in every joint, con-
cerning finger/toes, wrists/ankles, elbows and knees.
Occasionally one paw was missing in the histologic sec-
tions, or embedded in a way that made it impossible to
evaluate the degree of synovitis and bone/cartilage ero-
sion, and therefore, the total score/mouse is divided by
the number of joints evaluated.
Bacteriologic examination
The bacterial content in kidneys was determined at
sacrifice. The kidneys were aseptically removed,
mechanically homogenized, and diluted in 10 ml of PBS.
Viable counts were performed by culturing the tissue
suspension on horse-blood agar plates overnight to
determine the number of S. aureus CFUs.
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Assessment of bone mineral density
One femur from each mouse was subjected to periph-
eral quantitative computed tomography (pQCT) scan
with Stratec pQCT XCT Research M, software version
5.4 B (Norland, Fort Atkinson, WI, USA) at a resolu-
tion of 70 μm, as previously described [22]. Trabecular
bone mineral density (BMD) was determined with a
metaphyseal scan, which was performed at a distance
from the growth plate corresponding to 3% of the
length of the femur. The inner 45% of the area was
defined as the trabecular bone compartment. Cortical
BMD was determined with a mid-diaphyseal scan
located 36% of the length of the femur from the
growth plate.
Cytokine analysis
Serum levels of IL-6, IL-10, IL-17A, interferon (IFN)g,
and TNF-a were determined by using cytometric bead
assay (CBA) mouse Th1/Th2/Th17 kit (BD Biosciences,
Erebodegem, Belgium) according to the manufacturer’s
instructions. Samples were run on a FACSCanto II (BD
Biosciences). Detection limits were 1.4, 16.8, 0.8, 0.5,
and 0.9 pg/ml for IL-6, IL-10, IL-17A, IFN-g, and TNF-
a, respectively.
Analysis of serologic markers of bone and cartilage
remodeling
Serum levels of fragments of type I collagen were ana-
lyzed as markers of bone resorption by using a RatLaps
ELISA kit (Nordic Bioscience Diagnostics A/S, Herlev,
Denmark) according to the manufacturer’s instructions.
As a marker of cartilage degradation, serum levels of
cartilage oligomeric matrix protein (COMP) were deter-
mined by using an animal COMP ELISA assay (AnaMar
Medical AB, Gothenburg, Sweden).
Statistical evaluations
Statistical analyses were performed by using GraphPad
Prism (La Jolla, CA, USA) and R 2.10.1 [23]. Statistical
association between frequency of arthritis and treatment
was tested by using the Fisher Exact test. The change in
severity of clinical arthritis between treatments was
tested by using robust linear regression from the MASS
R-package. Differences in cytokine levels between inde-
pendent groups were tested by using Kruskal-Wallis
tests with the Dunn correction for multiple compari-
sons, whereas two-way analyses of variance (ANOVAs)
with Bonferroni posttests were used to assess the com-
bined effect of hormones and infection on BMD. Survi-
val analysis was performed by using the Kaplan-Meier
model, and differences in survival were tested by using
the log-rank test. A P value of ≤ 0.05 was considered
statistically significant.
Results
Estradiol ameliorates development and severity of S.
aureus-induced arthritis
The effect of estradiol treatment on the development
and severity of S. aureus-induced arthritis was studied
by inoculating ovariectomized mice treated with estra-
diol or placebo with S. aureus intravenously.
Development of S. aureus arthritis was significantly
inhibited by estradiol treatment; at day 10 after bacterial
inoculation, only eight (36%) of 22 estradiol-treated
mice had developed arthritis, as compared with 14
(70%) of 20 in the placebo group, and at day 14, the fre-
quency of arthritis was only 40% (four of 10) in the
estradiol-treated group, as compared with 90% (nine of
10) in the placebo-treated mice (Figure 1A). In addition,
estradiol-treated mice had significantly less severe clini-
cal arthritis as compared with placebo-treated mice (Fig-
ure 1B). Histopathologic evaluation of the joints did not
show any statistically significant reduction of synovitis
or joint destruction in estradiol-treated mice compared
with the placebo-treated group (Figure 1C, D).
To evaluate whether estradiol affected the general out-
come of S. aureus infection, the mortality, weight
change (as a sign of general health), and bacterial persis-
tence were studied.
No significant differences in survival rates were found
between estradiol-treated (20 of 26 mice, 74%) and pla-
cebo-treated (19 of 25 mice, 74%) groups. The weight
loss was not significantly different at any time in estra-
diol- as compared with placebo-treated mice (not
shown). Bacterial persistence in host tissue (kidneys)
was not affected by estradiol treatment; at day 14 after
bacterial inoculation, the median CFUs/two kidneys was
4.1 × 106 (range, 0 to 4.9 × 107) and 2.7 × 106 (range, 0
to 2.2 × 107) in estradiol- and placebo-treated mice,
respectively. Similarly, bacterial numbers in kidneys
obtained on days 3 and 7 did not differ between estra-
diol- or placebo-treated mice (not shown).
Estradiol treatment protects against systemic bone loss in
S. aureus infection
To study the effect of estradiol on S. aureus-induced
systemic bone loss, trabecular and cortical bone BMD
and cortical thickness were evaluated with pQCT. S.
aureus-infected, ovariectomized, placebo-treated mice
developed significant loss of trabecular bone (Figures 2A
and 3A). Estradiol treatment totally prevented the S.
aureus-induced trabecular bone loss, and at day 14 after
bacterial inoculation, the trabecular BMD had increased
significantly as compared with day 3 (Figure 2A). The
median trabecular BMD of 487 mg/cm3 at day 14 after
S. aureus inoculation of estradiol-treated mice was sig-
nificantly lower than the trabecular BMD of 588 mg/
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Figure 1 Effect of estradiol treatment on clinical course of Staphylococcus aureus infection. Frequency of arthritis (A), clinical severity of
arthritis (B), histologic evaluation of synovitis (C) and erosion (D) of bone and cartilage in joints, as evaluated microscopically. Solid circles,
estradiol-treated mice; open circles: placebo-treated mice. Values in B are given as mean ± SEM. Horizontal bars in C and D show median values,
and each symbol represents the histologic score for one mouse. Data in A and B are pooled from two separate experiments with 12 to 14 mice
per treatment group. *P < 0.05, as analyzed with the Fisher Exact test; ***P < 0.001, as analyzed with regression analysis.
Figure 2 Effect of estradiol treatment on Staphylococcus aureus-induced systemic bone loss as analyzed with peripheral quantitative
computed tomography (pQCT). Trabecular bone mineral density (BMD) (A), cortical BMD (B), and cortical thickness (C) in ovariectomized
estradiol- and placebo-treated S. aureus-infected mice and in ovariectomized, placebo-treated, uninfected controls. Horizontal bars show median
values, and each symbol represents one mouse. *P < 0.05; **P < 0.01; and ***P < 0.001; as analyzed with two-way ANOVAs with Bonferroni
posttests.
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cm3 in estradiol-treated uninfected mice at this time (P
< 0.05, not shown). Estradiol treatment also had a clear
bone-protective effect on cortical BMD, with signifi-
cantly higher cortical BMD in the estradiol- as com-
pared with the placebo-treated group at day 14 (Figure
2B). Cortical BMD was significantly increased at day 14,
as compared with day 3, in estradiol-treated mice (Fig-
ure 2B). The S. aureus infection induced a significant
reduction of cortical thickness in placebo- and estradiol-
treated mice at day 3 and in placebo-treated mice at day
14 (Figure 2C). Estradiol had no significant effect on
thickness of cortical bone.
Analyses of serum levels of bone and cartilage turn-
over markers showed that the levels of the bone-resorp-
tion marker RatLaps (type I collagen cross-links)
increased significantly during the infection in placebo-
treated but not in estradiol-treated mice (not shown).
The cartilage-turnover marker COMP was not signifi-
cantly increased after S. aureus infection, median level
in uninfected, ovariectomized mice being 2.1 U/L
(range, 1.8 to 2.2 U/L), as compared with 2.5 U/L
(range, 2.2 to 2.9 U/L) in infected, ovariectomized mice
or influenced by estradiol treatment.
Serum levels of IL-10 are increased in estradiol-treated S.
aureus-infected mice
To evaluate whether the protective effect of estradiol on
clinical signs of S. aureus-induced arthritis and bone
loss could be mediated by modulation of the systemic
cytokine responses, we analyzed the serum protein levels
of the proinflammatory cytokines TNF-a, IL-6, IFN-g,
and IL-17A and the antiinflammatory IL-10. Estradiol
treatment of infected mice induced significantly
increased serum protein levels of IL-10 at day 14 com-
pared with placebo-treated mice (Table 1). The serum
protein levels of TNF-a were significantly increased at
day 3 after bacterial inoculation in placebo-treated mice
compared with uninfected mice (Table 1). The serum
levels of IFN-g and IL-17A were low and were not
affected by the infection or by the estradiol treatment.
Figure 3 Relative contribution of ovariectomy and Staphylococcus aureus infection on bone loss as analyzed with peripheral
quantitative computed tomography (pQCT). Trabecular bone mineral density (BMD) (A) and representative pQCT images (B) at day 14 after
intravenous bacterial inoculation in sham-operated and ovariectomized S. aureus-infected mice. Samples from uninfected mice were taken at the
same time. Horizontal bars show median values. Solid triangles, sham-operated mice; solid circles, ovariectomized mice. Each symbol represents
one mouse. *P < 0.05; **P < 0.01; ***P < 0.001; as analyzed by two-way ANOVA with Bonferroni posttests.
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S. aureus infection and lack of endogenous estrogens
have an additive effect on systemic trabecular bone
resorption
Because both lack of endogenous estrogens and S. aur-
eus infection can induce systemic bone loss, we evalu-
ated the relative contribution of lack of endogenous
estrogens, as induced by ovariectomy, and S. aureus
infection on BMD, as measured with pQCT. In the pre-
sence of endogenous estrogens (sham-operated mice), S.
aureus infection induced an average decrease of trabecu-
lar BMD of 34% (that is, the median trabecular BMD
was 180 mg/cm3 at day 14 after bacterial inoculation as
compared with 274 mg/cm3 in uninfected mice) (Figure
3A, B). In ovariectomized mice (lacking endogenous
estrogens), the average decrease of trabecular BMD was
56% (that is, 65 mg/cm3 in infected mice at day 14 as
compared with 147 mg/cm3in uninfected mice (Figure
3A, B). Ovariectomy alone induced an average decrease
of trabecular BMD of 46% at day 21 after ovariectomy
(Figure 3A, B). Lack of endogenous estrogens and S.
aureus infection had a clear additive effect on trabecular
bone loss. Thus, ovariectomized, S. aureus-infected mice
showed a dramatic decrease of trabecular BMD, on
average, -76%, compared with sham-operated, unin-
fected mice (Figure 3A, B). Cortical BMD was not
affected by S. aureus infection of sham-operated mice,
but was significantly decreased in S. aureus-infected,
ovariectomized mice (not shown).
Discussion
S. aureus arthritis is a severe disease associated with sig-
nificant bone destruction that occurs despite antibiotic
treatment. Thus new treatment strategies are needed to
prevent the infection-induced bone loss. Estradiol has
been shown to ameliorate nonseptic arthritis and to pro-
tect against inflammation-induced bone loss in both
humans [16,24] and mice [17,19]. However, it has not
been investigated whether estradiol treatment can be
protective against septic arthritis or infection-induced
bone loss. Our study is the first to show that estradiol
treatment ameliorates the development of arthritis and
protects against systemic bone loss in S. aureus infection
in mice.
We found that estradiol treatment strongly reduced
both the frequency and severity of S. aureus-induced
arthritis at a later stage of S. aureus infection, impor-
tantly without affecting the bacterial clearance. These
findings suggests an immunomodulatory role of estra-
diol in septic arthritis similar to the immune-dampening
effects of estradiol previously demonstrated by us and
others in nonseptic, autoimmune arthritis in humans
and mice [16,17,19]. The antiarthritic effect of estradiol
in the present study was of a comparable magnitude
with treatment with antibiotics in our mouse model of
S. aureus arthritis [14,25]. Our data demonstrate that
estradiol-mediated suppression of the immune response
during S. aureus infection is beneficial for the host.
Even though we did not use antibiotic treatment in the
present study, one might expect an even better outcome
if estradiol had been combined with antibiotics.
In the present study, we demonstrated that estradiol
totally prevented the pronounced systemic loss of trabe-
cular bone noted in our previous studies of S. aureus
infection in mice [14,15]. The trabecular BMD was pre-
served in estradiol-treated, infected mice at day 3 after
bacterial inoculation and increased throughout the
experiment, in contrast to the placebo-treated mice,
which had a significant decrease of trabecular BMD 3
days after bacterial inoculation, with continuous loss of
trabecular BMD during the study period. The higher
trabecular BMD seen in estradiol-treated mice at day 14
as compared with day 3 was likely to reflect that the
peak of the estradiol effect in this bone compartment
was not reached until the later time. Estradiol was also
protective against decrease of cortical BMD, but only at
a later stage of the infection, with significantly higher
cortical BMD in the estradiol-treated mice at day 14
after S. aureus inoculation. These temporal differences
of the protective effects of estradiol in the trabecular
and cortical bone compartments is likely explained by
the higher bone-remodeling rate in trabecular bone, ren-
dering this compartment more responsive to factors
affecting bone metabolism.
Collectively, these bone-protective effects of estradiol
in S. aureus infection are in good accord with our pre-
vious studies showing a bone-protective effect of estro-
gen in nonseptic, autoimmune arthritis in mice [19,20].
Our data show that the serum levels of IL-10 are
increased in estradiol-treated mice. It is known that
estradiol induces IL-10 production [26-28] and that IL-
10 can inhibit osteoclast activity and differentiation in
Table 1 Serum cytokine levels in Staphylococcus aureus-
infected mice treated with estradiol or placebo and in








IL-10 16.8 (16.8-16.8) 8.4 (8.4-16.8) 18.2 (12.6-172.4)bc
TNF-a 5.7 (3.9-8.7) 18.4 (15.0-23.6)d 20.4 (15.0-32.1)
IL-6 3.3 (1.7-92.3) 49.4 (24.6-454.8) 49.3 (13.3-617.0)
IFN-g 1.2 (0.5-1.5) 1.6 (1.5-2.4) 2.0 (1.1-3.8)
IL-17A 1.2 (0.8-1.7) 1.8 (1.6-3.0) 2.6 (1.3-8.0)
aValues in pictograms per milliliter are given as medians (interquartile ranges).
All mice were ovariectomized. Uninfected mice were treated with placebo.
Infected mice were killed at day 14 after bacterial inoculation. bP < 0.05, as
compared with infected, placebo-treated mice. cP < 0.01; dP < 0.001, as
compared with uninfected controls. Statistical analyses were done with the
Kruskal-Wallis test followed by Dunn multiple-comparison test.
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mice and humans [12,29,30]. Thus, it is likely that the
increased serum levels of IL-10 in estradiol-treated mice
contribute to the protective effect of estradiol on clinical
development of arthritis as well as on systemic bone
loss. Interestingly, estradiol was recently shown to
increase regulatory T cell-mediated suppression of
osteoclast differentiation and bone resorption in vitro
via induction of IL-10 and TGF-b production [31]. Our
finding of increased IL-10 levels at later stages of S. aur-
eus infection suggests that the cellular source of estra-
diol-induced IL-10 might be regulatory T cells, but this
remains to be investigated. Finally, we previously
showed that IL-10 ameliorates S. aureus arthritis in
mice [11], and others demonstrated that estradiol ame-
liorates adjuvant-arthritis in rodents in conjunction with
an increased IL-10 response [32]. Another possible
mechanism behind the increased IL-10 levels is induc-
tion of IL-10 production by proinflammatory cytokines
(for example, TNF-a and IL-6). However, we did not
find any correlation between the levels of IL-10 and
TNF-a on an individual basis indicating independence
between these cytokine responses, but further studies
are needed.
Even though we found a significant effect of estradiol
treatment on clinical signs of arthritis, supporting an
antiinflammatory effect of estradiol treatment, in our
model, the effects on BMD might of course also be due
to the anabolic effect of estradiol on bone.
The role of estrogens in host defense against infec-
tions is not fully understood, as reviewed by Marriott et
al. [33]. Estradiol treatment in our study did not influ-
ence the host ability to clear bacteria from infected tis-
sues and general signs of bacterial burden (for example,
weight loss or mortality were very similar in estradiol
and placebo-treated groups).
In contrast to the clear antiresorptive effect of estra-
diol on systemic bone, we did not find any significant
reduction of joint destruction in estradiol-treated mice,
even though a tendency was present for a protective
role of estradiol. This is also in contrast to our previous
reports on a strong protective effect of estradiol on joint
destruction in nonseptic, collagen-induced arthritis in
mice [19]. Several reasons are possible for this discre-
pancy. First, the joint destruction might be caused by
different mechanisms at the cellular and/or molecular
level in septic and nonseptic arthritis. Second, the local
levels of inflammatory cytokines might be higher in the
joints of S. aureus-infected mice than in nonseptic
arthritic joints exceeding the immunosuppressive capa-
city of estradiol. Third, the capacity of S. aureus exists
to activate osteoclasts directly or indirectly via increased
RANKL expression on osteoblasts [34,35]. However, we
could not demonstrate any reduction of joint
destruction in a previous study using RANKL-targeted
therapy in S. aureus arthritis in mice [14,15].
Interestingly, our results show that a postmenopausal
state, induced by ovariectomy, and S. aureus infection
have strong additive effects on loss of trabecular bone
(that is, ovariectomized and infected mice showed an
average decrease of 76% of their trabecular BMD com-
pared with sham-operated uninfected mice).
It is not known whether severe S. aureus infections, or
other bacterial systemic infections, induce systemic bone
loss, and thereby increase risk for osteoporosis and
related fractures, in patients in general or in postmeno-
pausal women in particular. However, it has been clearly
demonstrated that chronic inflammation, such as in
rheumatoid arthritis, and a postmenopausal state have
an additive effect on bone loss and osteoporosis. The
frequency of osteoporosis is approximately 50% in post-
menopausal women with RA [36,37]. Our finding of a
dramatic infection-induced systemic bone loss in experi-
mental menopause warrants further studies of bone loss
in postmenopausal women with severe bacterial
infections.
Conclusions
In conclusion, our study of arthritis and bone loss in S.
aureus infection in mice provides evidence for an antiar-
thritic and strong bone-protective role of estradiol in
infectious arthritis. Our findings may have future impli-
cations for the treatment of bacterial arthritis with
estrogens or selective estrogen-receptor modulators,
SERMs in combination with antibiotics.
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